Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.

Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, Welker C, Gillies SD, Strittmatter W, Zips D, Handgretinger R, Schilbach K.

Oncoimmunology. 2017 Apr 28;6(6):e1323161. doi: 10.1080/2162402X.2017.1323161. eCollection 2017.

2.

Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models.

Eckert F, Schmitt J, Zips D, Krueger MA, Pichler BJ, Gillies SD, Strittmatter W, Handgretinger R, Schilbach K.

Cancer Immunol Immunother. 2016 Aug;65(8):1003-13. doi: 10.1007/s00262-016-1863-0. Epub 2016 Jul 4.

PMID:
27376889
3.

Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T, Braumüller H, Schmitt J, Eyrich M, Schleicher S, Seitz C, Erbacher A, Pichler BJ, Müller H, Tighe R, Lim A, Gillies SD, Strittmatter W, Röcken M, Handgretinger R.

Oncoimmunology. 2015 Mar 19;4(7):e1014760. eCollection 2015 Jul.

4.

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Popiel HA, Takeuchi T, Burke JR, Strittmatter WJ, Toda T, Wada K, Nagai Y.

Neurotherapeutics. 2013 Jul;10(3):440-6. doi: 10.1007/s13311-013-0184-7. Review.

5.

Bathing the brain.

Strittmatter WJ.

J Clin Invest. 2013 Mar;123(3):1013-5. doi: 10.1172/JCI68241. Epub 2013 Feb 22.

6.

Alzheimer’s disease: the new promise.

Strittmatter WJ.

J Clin Invest. 2012 Apr;122(4):1191. No abstract available.

7.

Medicine. Old drug, new hope for Alzheimer's disease.

Strittmatter WJ.

Science. 2012 Mar 23;335(6075):1447-8. doi: 10.1126/science.1220725. No abstract available.

PMID:
22442467
8.

The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.

Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, Takeuchi T, Toda T, Wada K, Nagai Y.

J Amino Acids. 2011;2011:265084. doi: 10.4061/2011/265084. Epub 2011 Jun 30.

9.

Genome-wide scan of copy number variation in late-onset Alzheimer's disease.

Heinzen EL, Need AC, Hayden KM, Chiba-Falek O, Roses AD, Strittmatter WJ, Burke JR, Hulette CM, Welsh-Bohmer KA, Goldstein DB.

J Alzheimers Dis. 2010;19(1):69-77. doi: 10.3233/JAD-2010-1212.

10.

A genome-wide investigation of SNPs and CNVs in schizophrenia.

Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, Kasperaviciūte D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, McEvoy JP, Keefe RS, Fisher EM, St Jean PL, Giegling I, Hartmann AM, Möller HJ, Ruppert A, Fraser G, Crombie C, Middleton LT, St Clair D, Roses AD, Muglia P, Francks C, Rujescu D, Meltzer HY, Goldstein DB.

PLoS Genet. 2009 Feb;5(2):e1000373. doi: 10.1371/journal.pgen.1000373. Epub 2009 Feb 6. Erratum in: PLoS Genet. 2009 Mar;5(3). doi: 10.1371/annotation/e0196ebb-de40-453f-8f8c-791b126618da.

11.

Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.

Lai TS, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, Strittmatter WJ, Greenberg CS.

Chem Biol. 2008 Sep 22;15(9):969-78. doi: 10.1016/j.chembiol.2008.07.015.

12.

Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.

Weinberg JB, Volkheimer AD, Mihovilovic M, Jiang N, Chen Y, Bond K, Moore JO, Gockerman JP, Diehl LF, de Castro CM, Rizzieri DA, Levesque MC, Dekroon R, Strittmatter WJ.

Leukemia. 2008 Dec;22(12):2184-92. doi: 10.1038/leu.2008.241. Epub 2008 Sep 11.

PMID:
18784741
13.

Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay.

Hamuro L, Zhang G, Tucker TJ, Self C, Strittmatter WJ, Burke JR.

Assay Drug Dev Technol. 2007 Oct;5(5):629-36.

PMID:
17939755
14.

Apolipoprotein E alleles and sensorineural hearing loss.

O'Grady G, Boyles AL, Speer M, DeRuyter F, Strittmatter W, Worley G.

Int J Audiol. 2007 Apr;46(4):183-6.

PMID:
17454231
15.

High-fat/high-cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL.

Mihovilovic M, Robinette JB, DeKroon RM, Sullivan PM, Strittmatter WJ.

J Lipid Res. 2007 Apr;48(4):806-15. Epub 2007 Jan 30.

16.

Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice.

Osorio C, Sullivan PM, He DN, Mace BE, Ervin JF, Strittmatter WJ, Alzate O.

Neurobiol Aging. 2007 Dec;28(12):1853-62. Epub 2006 Oct 16.

PMID:
17050040
17.

Phage display screening for peptides that inhibit polyglutamine aggregation.

Kenan DJ, Strittmatter WJ, Burke JR.

Methods Enzymol. 2006;413:253-73.

PMID:
17046401
18.

APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2.

DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ.

Circ Res. 2006 Oct 13;99(8):829-36. Epub 2006 Sep 14.

PMID:
16973905
19.

Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria.

Puranam KL, Wu G, Strittmatter WJ, Burke JR.

Biochem Biophys Res Commun. 2006 Mar 10;341(2):607-13. Epub 2006 Jan 13.

PMID:
16427603
20.

APOE2 allele increased in tardive dyskinesia.

Halford J, Mazeika G, Slifer S, Speer M, Saunders AM, Strittmatter WJ, Morgenlander JC.

Mov Disord. 2006 Apr;21(4):540-2.

PMID:
16261623
21.

Apolipoprotein E and brain injury: implications for children.

Blackman JA, Worley G, Strittmatter WJ.

Dev Med Child Neurol. 2005 Jan;47(1):64-70. Review. No abstract available.

22.

Disrupted spermine homeostasis: a novel mechanism in polyglutamine-mediated aggregation and cell death.

Colton CA, Xu Q, Burke JR, Bae SY, Wakefield JK, Nair A, Strittmatter WJ, Vitek MP.

J Neurosci. 2004 Aug 11;24(32):7118-27.

23.

Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.

Popiel HA, Nagai Y, Onodera O, Inui T, Fujikake N, Urade Y, Strittmatter WJ, Burke JR, Ichikawa A, Toda T.

Biochem Biophys Res Commun. 2004 May 14;317(4):1200-6.

PMID:
15094397
24.

Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.

Lai TS, Tucker T, Burke JR, Strittmatter WJ, Greenberg CS.

J Neurochem. 2004 Mar;88(5):1253-60.

25.

APOE genotype-specific differences in human and mouse macrophage nitric oxide production.

Colton CA, Needham LK, Brown C, Cook D, Rasheed K, Burke JR, Strittmatter WJ, Schmechel DE, Vitek MP.

J Neuroimmunol. 2004 Feb;147(1-2):62-7.

PMID:
14741429
26.

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.

Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, Yamaguchi M, Strittmatter WJ, Burke JR, Toda T.

Hum Mol Genet. 2003 Jun 1;12(11):1253-9.

PMID:
12761040
27.

ApoE genotype-specific inhibition of apoptosis.

DeKroon RM, Mihovilovic M, Goodger ZV, Robinette JB, Sullivan PM, Saunders AM, Strittmatter WJ.

J Lipid Res. 2003 Aug;44(8):1566-73. Epub 2003 May 16.

28.

APOE genotype is a risk factor for neuropathy severity in diabetic patients.

Bedlack RS, Edelman D, Gibbs JW 3rd, Kelling D, Strittmatter W, Saunders AM, Morgenlander J.

Neurology. 2003 Mar 25;60(6):1022-4.

PMID:
12654974
29.

Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.

Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, Furukawa K, Herlyn D.

Cancer Immunol Immunother. 2003 Mar;52(3):145-54. Epub 2003 Feb 11.

PMID:
12649743
30.

In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.

Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT.

Arch Biochem Biophys. 2003 Feb 1;410(1):1-6.

PMID:
12559971
31.

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT.

Nat Neurosci. 2002 Aug;5(8):731-6.

PMID:
12089530
32.

Expanded polyglutamine stretches form an 'aggresome'.

Shimohata T, Sato A, Burke JR, Strittmatter WJ, Tsuji S, Onodera O.

Neurosci Lett. 2002 May 3;323(3):215-8.

PMID:
11959423
33.

Molecular biology of apolipoprotein E.

Strittmatter WJ, Bova Hill C.

Curr Opin Lipidol. 2002 Apr;13(2):119-23. Review.

PMID:
11891413
34.

Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death.

Ren H, Nagai Y, Tucker T, Strittmatter WJ, Burke JR.

Biochem Biophys Res Commun. 2001 Nov 2;288(3):703-10.

PMID:
11676500
35.

Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms.

Strittmatter WJ.

Biochem Soc Symp. 2001;(67):101-9. Review.

PMID:
11447826
36.

Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology.

Dranovsky A, Vincent I, Gregori L, Schwarzman A, Colflesh D, Enghild J, Strittmatter W, Davies P, Goldgaber D.

Neurobiol Aging. 2001 Jul-Aug;22(4):517-28.

PMID:
11445251
37.

Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice.

Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD.

Exp Neurol. 2001 May;169(1):13-22.

PMID:
11312553
38.

Apolipoprotein E and Alzheimer's disease.

Strittmatter WJ.

Ann N Y Acad Sci. 2000;924:91-2. Review.

PMID:
11193808
39.

Apolipoprotein E and neuromuscular disease: a critical review of the literature.

Bedlack RS, Strittmatter WJ, Morgenlander JC.

Arch Neurol. 2000 Nov;57(11):1561-5. Review.

PMID:
11074787
40.

Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients.

Chew ST, Newman MF, White WD, Conlon PJ, Saunders AM, Strittmatter WJ, Landolfo K, Grocott HP, Stafford-Smith M.

Anesthesiology. 2000 Aug;93(2):325-31.

PMID:
10910477
41.

The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection.

Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, Wallace DM, Strittmatter WJ, Roses AD.

Biochim Biophys Acta. 2000 Jul 26;1502(1):85-94. Review.

42.

Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening.

Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR.

J Biol Chem. 2000 Apr 7;275(14):10437-42.

43.

Polyglutamine domain proteins with expanded repeats bind neurofilament, altering the neurofilament network.

Nagai Y, Onodera O, Strittmatter WJ, Burke JR.

Ann N Y Acad Sci. 1999;893:192-202.

PMID:
10672238
44.

Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.

Wild MK, Strittmatter W, Matzku S, Schraven B, Meuer SC.

J Immunol. 1999 Aug 15;163(4):2064-72. Erratum in: J Immunol 2000 May 15;164(10):5531.

45.

Expanded polyglutamine domain proteins bind neurofilament and alter the neurofilament network.

Nagai Y, Onodera O, Chun J, Strittmatter WJ, Burke JR.

Exp Neurol. 1999 Feb;155(2):195-203.

PMID:
10072295
46.

Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.

Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ, Gentile V, Peluso G, Blass JP.

J Neurochem. 1999 Mar;72(3):889-99. Review.

47.
48.

Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts.

Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ, Blass JP.

Dev Neurosci. 1998;20(4-5):462-8.

PMID:
9778585
49.

Peripheral sensory nerve defects in apolipoprotein E knockout mice.

Fullerton SM, Strittmatter WJ, Matthew WD.

Exp Neurol. 1998 Sep;153(1):156-63.

PMID:
9743578
50.

Human apolipoprotein E accelerates microtubule polymerization in vitro.

Scott BL, Welch K, deSerrano V, Moss NC, Roses AD, Strittmatter WJ.

Neurosci Lett. 1998 Apr 3;245(2):105-8.

PMID:
9605496

Supplemental Content

Loading ...
Support Center